Data shows SeptiCyte™ LAB can distinguish SIRS from sepsis better than other parameters
May 18, 2016 – SEATTLE. Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, today announced that SeptiCyte™ LAB outperformed other clinical and laboratory parameters at distinguishing infection-negative systemic inflammation response syndrome (SIRS) from infection-positive systemic inflammation (sepsis). The data from the VENUS study were presented by Dr. Russell R. Miller, III of Intermountain Medical Center at the American Thoracic Society International Conference in San Francisco.
Dr. Miller’s presentation describes the relative performance of various clinical and laboratory parameters, individually and in combination, compared to SeptiCyte™ LAB. SeptiCyte™ LAB performed better at distinguishing SIRS from sepsis than any combination of variables. Additionally, the inclusion of other variables with SeptiCyte™ scores did not improve its diagnostic accuracy.
“Dr. Miller’s results indicate that SeptiCyte™ alone provides better information for distinguishing SIRS from sepsis than other clinical and laboratory parameters,” said Dr. Roslyn Brandon, President and CEO of Immunexpress. “This research indicates that analyzing a patient’s immune response provides a clear solution to the major issue of quickly and effectively diagnosing sepsis.”
Sepsis is a life-threatening condition that arises when the body’s response to infection damages its own tissues and organs. Diagnosis of sepsis today relies on medical impression based on a combination of clinical parameters and later pathogen detection and therefore has serious limitations in respect to speed and sensitivity. The Immunexpress SeptiCyte™ LAB solution evaluates the patient’s own immune response to infection to aid clinicians in quickly and accurately diagnosing sepsis in patients suspected of sepsis.